Zopiclone versus placebo for short-term treatment of insomnia in patients with advanced cancer: study protocol for a double-blind, randomized, placebo-controlled, clinical multicenter trial

Gunnhild Jakobsen 1,2*, Morten Engstrøm 3,4, Ørnulf Paulsen 1,5, Karin Sjue 6, Sunil X. Raj 1,2, Morten Thronæs 1,2, Marianne Jensen Hjermstad 7, Stein Kaasa 7, Peter Fayers 8 and Pål Klepstad 9,10

Abstract

Background: Despite the high prevalence of insomnia in patients with advanced cancer, there are no randomized controlled trials on pharmacological interventions for insomnia in this group of patients. A variety of pharmacological agents is recommended to manage sleep disturbance for insomnia in the general population, but their efficacy and safety in adults with advanced cancer are not established. Thus, there is a need to evaluate the effectiveness of medications for insomnia in order to improve the evidence in patients with advanced cancer. One of the most used sleep medications at present in patients with cancer is zopiclone.

Methods: This is a randomized, double-blind, placebo-controlled, parallel-group, multicenter trial. A total of 100 patients with metastatic cancer who report insomnia will be randomly allocated to zopiclone or placebo. The treatment duration with zopiclone/placebo is 6 consecutive nights. The primary endpoint is patient-reported sleep quality during the final study night (night 6) assessed on a numerical rating scale of 0–10, where 0 = Best sleep and 10 = Worst possible sleep. Secondary endpoints include the mean patient-reported total sleep time and sleep onset latency during the final study night (night 6).

Discussion: Results from this study on treatment of insomnia in advanced cancer will contribute to clinical decision-making and improve the treatment of sleep disturbance in this patient cohort.

Trial registration: ClinicalTrials.gov, NCT02807922. Registered on 21 June 2016.

Keywords: Advanced cancer, Insomnia, Pharmacological treatment, Randomized controlled trial

Background

Sleep disturbance is frequent in patients with advanced cancer and might impair the tolerance of other symptoms and reduce quality of life [1, 2]. An observational study in different settings of palliative care found that sleep disturbance was reported by 61% of the cancer patients [3]. This prevalence corresponds with results from another multicenter study where 78% of the patients with advanced cancer experienced poor sleep quality [4]. Insomnia is the most prevalent sleep disorder both in the general population and among patients with cancer [5]. The prevalence of insomnia in the general population, when defined according to formal diagnostic systems, is approximately 10% [6, 7]. The prevalence of insomnia in patients with cancer is reported to be three-fold higher [8]. Insomnia in the context of cancer is characterized as difficulty initiating sleep and/or
difficulty maintaining sleep, which impairs daytime functioning [9].

Sleep quality in patients with advanced cancer might be influenced by several factors such as pain, fatigue, and anxiety, worries about the future, little daytime activity, interrupted sleep because of procedures, a large number of medications, and systemic inflammation [1, 10–12]. In palliative care cancer populations, where life expectancy is limited, the goal of symptom relief usually overrides the concerns of long-term side effects [13]. However, because of polypharmacy and advanced cancer disease, the patients are more vulnerable to potential short-term side effects. Thus, results from studies on pharmacological treatment for insomnia in non-cancer populations are not necessarily applicable to patients with advanced cancer. A careful selection of sleep medications that benefit advanced cancer patients is therefore important.

A combined step-wise pharmacological and non-pharmacological approach is recommended in the treatment of insomnia in cancer patients [14]. In cases where sleep disturbance is due to the cancer or its treatment, the first step is to remove the causative condition if possible (e.g., pain, dyspnea, anxiety) [15]. The second step should include non-pharmacological sleep interventions with cognitive behavioral therapy [16]. Cognitive behavioral therapy for insomnia (CBT-I) usually consists of psychoeducation/sleep hygiene, relaxation training, stimulus control therapy, and cognitive therapy [17]. In a European guideline, CBT-I is recommended as the first line treatment for chronic insomnia in adults of any age [18]. A randomized controlled trial (RCT) supported the efficacy of CBT-I for chronic insomnia associated with cancer [19]. However, a major limitation for the routine implementation of CBT-I in cancer clinics is the lack of mental health professionals formally trained in this approach. In addition, the number of CBT sessions, usually four to eight sessions, can be too demanding for patients during cancer treatment or for patients with advanced cancer disease. Thus, when life expectancy is short, medication is recommended as the treatment of choice for insomnia because of its rapid effect [20, 21].

To manage insomnia successfully, pharmacological treatment for insomnia should reduce sleep latency, increase sleep maintenance, and improve sleep quality [22]. A variety of pharmacological agents against insomnia has been recommended for use in the general population, but their efficacy and safety in adults with cancer are not established [16]. A Cochrane Database review of clinical trials assessing the safety and efficacy of benzodiazepines or benzodiazepine receptor agonists in treating insomnia in palliative care identified no articles that met the inclusion criteria [23]. In 2013, Howell et al. reviewed the evidence base for the management of cancer-related sleep disturbance (insomnia and insomnia syndrome) in oncology practice, and identified no RCT data involving pharmacological interventions for insomnia in advanced cancer [16]. Despite the lack of evidence, several classes of sleep medications are used to treat sleep disturbance in patients with cancer [24]. In a European multicenter study, the most frequently used hypnotic drug was the non-benzodiazepine hypnotic agent zopiclone, which was used by 348 of 2282 patients with advanced cancer [24]. Therefore, we designed a double-blind, placebo-controlled, parallel-group RCT to evaluate the short-term effectiveness of zopiclone on self-reported sleep quality in patients with advanced metastatic cancer who report insomnia.

Methods
The trial adheres to the Standard Protocol Items: Recommendations for Interventional trials (SPIRIT) checklist (see Additional file 1).

Study design
This study is designed as a randomized, double-blind, placebo-controlled, parallel-group, multicenter, phase IV clinical trial.

Study objectives and endpoints
The primary objective is to study the short-time effectiveness of zopiclone on patient-reported subjective sleep quality in patients with advanced cancer who report insomnia. The primary endpoint is patient-reported sleep quality during the final study night with treatment (night 6) assessed on a numerical rating scale (NRS) of 0–10, where 0 = Best sleep and 10 = Worst possible sleep. The secondary objective is to study the effectiveness of zopiclone on mean self-reported total sleep time and sleep onset latency. Table 1 summarizes the objectives and endpoints including the explorative objectives.

Sample size
The primary variable used in the sample size calculation is patient-reported sleep quality on an NRS of 0–10 during night 6 (the last study night with treatment). The defined minimal clinical important difference (MCID) between the two study groups (zopiclone/placebo) is 2 for the primary outcome sleep quality, scored on the NRS. Due to the lack of relevant data for MCID for NRS on sleep quality, this number was chosen based upon NRS in cancer pain studies [25, 26]. Data obtained in recent studies suggest an expected standard deviation of 2.75 [27–33]. Using a significance level of 5%, these assumptions indicate that for 80% power 33 patients are needed in each group. For 90% power a sample size of 42 per group is required. The study will aim for a 90% power and allow for an expected number of 8 drop-outs...
during the study period (6 nights). The study will include 50 patients in each treatment arm.

**Eligibility criteria**
Patients with advanced cancer with insomnia syndrome will be recruited by study personnel from three outpatient units at hospitals in Norway. Cancer patients are screened using the following two questions: “Do you have problems with your sleep or sleep disturbance on average for 3 or more nights a week? “Does the problem with your sleep negatively affect your daytime functioning?” Informed consent will be obtained for all patients included in the study.

**Inclusion criteria**
The criteria for inclusion in the study are:

- Histologically verified malignant disease
- Presence of metastatic/disseminated disease
- Presence of insomnia syndrome in the context of cancer defined as [9]:  
  - Self-reported difficulty initiating sleep (greater than 30 min to sleep onset) and/or difficulty maintaining sleep (greater than 30 min nocturnal waking time) and/or waking up earlier than desired; and  
  - Sleep difficulty at least 3 nights per week; and  
  - Sleep difficulty that causes significant impairment of daytime functioning (the patient will be asked if sleep difficulty results in altered daytime function, i.e., feeling tired, lack of energy)
- Patient at least 18 years of age
- Ability to comply with all study procedures
- Provision of signed informed consent

**Exclusion criteria**
The following criteria are grounds for exclusion from the study:

- Ongoing treatment or previous treatment (within last 4 weeks) for more than 3 consecutive days with medications given for insomnia
- Adverse reactions to zopiclone
- History of substance abuse
- Concomitant use of rifampicin and erythromycin
- Any other contraindication listed on the summary of product characteristics of zopiclone  
  - Myasthenia gravis  
  - An established diagnosis of severe impairment of respiratory function  
  - An established diagnosis of severe hepatic insufficiency (Child-Pugh grade B or C)  
  - An established diagnosis of sleep apnea  
  - Known hypersensitivity to the drug or to any component in its formulation
- Unfit for participation for any reason as judged by the investigator
- Pregnancy or lactation
- Women of reproductive age not willing or unable to employ an effective method of contraception (sterilization, using IUD or oral contraception)
- Scheduled surgery within the next week
- Needing change in scheduled opioid dose at baseline (study visit 1)
- Scheduled intravenous administration of chemotherapy during the study period (from baseline to day 8) or intravenous administration of chemotherapy during the last week

**Table 1** Primary, secondary, and explorative objectives and related endpoints and assessments

| Objective | Endpoint Assessment method |
|-----------|---------------------------|
| Primary   | To study the short-time effectiveness of zopiclone on patient-reported subjective sleep quality | Patient-reported sleep quality the last study night (night 6)  
  Numerical rating scale 0–10, 0 = Best sleep, 10 = Worst possible sleep |
| Secondary | To study the short-time effectiveness of zopiclone on patient-reported TST | Patient-reported TST (minutes) the last study night (night 6)  
  Sleep diary |
|           | To study the short-time effectiveness of zopiclone on patient-reported SOL | Patient-reported SOL (minutes) the last study night (night 6)  
  Sleep diary |
| Explorative | To study the short-time effectiveness of zopiclone on overall patient-reported sleep quality | Patient-reported overall sleep quality over a week time interval  
  Pittsburgh Sleep Quality Index |
|           | To study the short-time effectiveness of zopiclone on objectively measured TST, SOL, SE, WASO, and NWAK | TST (minutes), SOL (minutes), SE (percent), WASO and NWAK during the last study night (night 6)  
  Actigraphy |
|           | To study the short-time effectiveness of zopiclone on patient-reported TST, SOL, SE, WASO, and NWAK | TST (minutes), SOL (minutes), SE (percent), WASO, and NWAK during the last study night (night 6)  
  Sleep diary |
|           | To study the short-time effectiveness of zopiclone on self-reported daytime sleepiness | Daytime sleepiness in the morning after night 6  
  Karolinska Sleepiness Scale |

TST total sleep time, SOL sleep onset latency, SE sleep efficiency, WASO wake after sleep onset, NWAK number of awakenings
Change in corticosteroid dose last week before baseline or planned dose change in corticosteroid dose within 7 days from baseline

Randomization, blinding, and study monitoring
Patients who have consented to participate in the study will be randomized using a web-based randomization system developed and administered by the Unit for Applied Clinical Research, Institute of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway. Patients are randomized to either the zopiclone arm (Arm A) or the placebo arm (Arm B) (Fig. 1). Randomization will be stratified based on study center. Patients are allocated with equal probabilities to treatment. The treatment is double-blind; i.e., the investigational medicinal product (IMP) is blinded for the patient, site, and study personnel by identical appearance, shape, and color as well as identical labeling and packing. In a medical emergency, the investigator will be able to break the code for an individual patient by contacting the person on call at the hospital pharmacy. The external monitor for the trial is the Unit for Applied Clinical Research, NTNU.

Treatment
The treatment is 6 subsequent nights with zopiclone or placebo. For this study, zopiclone “Actavis” 3.75 mg, 5 mg, and 7.5 mg (active comparator) are defined as the IMP. Kragerø Tablettproduksjon AS, Kragerø, Norway will produce, blind, pack, and label the IMP. Patients will receive the IMP in custom-made capsules containing zopiclone Actavis 3.75 mg, 5 mg, or 7.5 mg or placebo administered once daily (taken in the evening 30 min before going to bed). Each patient will receive six boxes, with each box containing the allocated IMP for 2 nights. Each box is labeled with dose level according to the titration. The initial dose of zopiclone/placebo is 3.75 mg/day started after 1 night with sleep quality assessment and symptom assessment. The study personnel will evaluate the patient by phone after 2 and 4 nights of being on study medication by asking the question “Please circle the number that best describes how you feel now” on an NRS, where 0 = Best sleep and 10 = Worst possible sleep. If the NRS value is ≥4 at evaluation (Fig. 2), the dose of zopiclone/placebo is increased one dose level according to dose level 1 = 3.75 mg zopiclone/placebo; dose level 2 = 5 mg zopiclone/placebo; dose level 3 = 7.5 mg zopiclone/placebo. If NRS is <4 at evaluation, the patient continues on the same dose level. If patients titrated to dose level 2 at night 4 experience excess sedation during the daytime, the dose can be decreased to dose level 1 for nights 5 and 6. The patients will indicate in the sleep diary whether they have taken their trial drug or not and state the reason, given by the alternatives forgotten, side effects, or other, if they omitted the trial medication. Each patient will be instructed to contact the investigator immediately should they manifest any signs or symptoms they perceive as serious. End-of-protocol therapy is defined as therapy after 6 nights of treatment.

![Consolidated Standards of Reporting Trials (CONSORT) flow diagram](image-url)
nights with treatment. Further treatment is the responsibility of the physician in charge of patient treatment. The protocol was considered as a low-risk study, and according to Norwegian legislations, a data monitoring committee was not needed.

Withdrawal criteria
Patients may withdraw from the trial at any time at their own request. Patients can be withdrawn from the study at the discretion of the treating physician if they have an acute complication of the cancer or the treatment, including sudden changes in their clinical condition such as cardiovascular events or sepsis.

Data collection and statistics
The following variables will be recorded in the web-based case report form, which is administered by the Unit for Applied Clinical Research, (NTNU): date of birth, weight, height, concomitant diseases, psychiatric history, department category (i.e., palliative care unit or general oncology ward), principal cancer diagnosis (International Classification of Diseases (ICD-10)), date of the principal cancer diagnosis, site of metastases (bone, liver, lung, central nervous system, other), present anticaner treatment, and medications taken in the last 24 h. The Karnofsky Performance Status (KPS) scale will be used to assess performance status [34]. In addition, history and duration of opioid consumption will be obtained. Clinical chemistry results (hemoglobin, creatinine, C-reactive protein, albumin, and bilirubin) will be obtained from the medical record. Results collected less than 7 days before inclusion are considered valid.

Trial procedures
The SPIRIT schedule (Fig. 3) illustrates the schedule of the trial procedures from baseline to end of study.

Patient-reported outcome measures
The European Association for Palliative Care (EAPC) basic dataset
This questionnaire includes assessment of symptoms such as pain, tiredness, drowsiness, nausea, lack of appetite, shortness of breath, depression, anxiety, wellbeing, sleep, constipation, and vomiting [35]. Patient-reported sleep quality is assessed on an NRS of 0–10, where 0 = Best sleep and 10 = Worst possible sleep.

The European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire for palliative cancer patients (EORTC QLQ-C15-PAL)
This questionnaire for quality of life (QOL) in patients on palliative cancer care contains two functional scales.
(physical, emotional), two symptom scales (fatigue, pain), five single items (dyspnea, insomnia, appetite loss, nausea, constipation), and one item on global QOL. All items except global QOL are scored on a 4-point categorical scale covering the past week. There is one 7-point question on overall QOL [36].

**Karolinska Sleepiness Scale (KSS)**

The KSS is a 9-point Likert scale based on a self-reported, subjective assessment of the patient’s level of drowsiness at the time [38]. The questionnaire, with nine options ranging from “Very alert” to “Very sleepy, fighting sleep, difficulty staying awake” and including “Neither sleepy nor alert” and “Sleepy but no effort to remain awake” is scored from 1 to 9.

**Health-related quality of life (HRQOL): mental health**

HRQOL is assessed by the Short Form-36 (SF-36) questionnaire. The SF-36 is grouped into eight multi-item scales [39]. This trial will use five questions from the mental health scale.

**Satisfaction**

At the end of treatment, the patient will be asked a question on satisfaction: “How satisfied are/were you with the effect of the sleep medication?” Satisfaction with the use of sleep medication will be coded as either “not satisfied” (i.e.,...
not at all satisfied, dissatisfied, and neither satisfied nor dissatisfied) or “satisfied” (i.e., satisfied and very satisfied) [40].

**Sleep diary**
The sleep diary is a subjective daily report of sleep and sleep disturbances, typically completed when getting up in the morning, to provide an estimate of the previous night’s sleep [41]. The sleep diary includes sleep onset latency (SOL), number of awakenings (NWAK), wake after sleep onset (WASO), terminal wakefulness (TWAK), total sleep time (TST), final awakening time, and sleep efficiency (SE). The sleep diary will be adapted according to the consensus recommendation for sleep diaries [42]. The trial will use the Norwegian version of the sleep diary published by the Norwegian Competence Center for Sleep Disorders, Haukeland University Hospital [43].

**Objective measure of sleep**
*Actigraphy* is a method of assessment that distinguishes between wakefulness and sleep from the presence or absence of limb movement [44]. The Actiwatch is a small wristwatch-sized device which is used to assess sleep-wake cycles [45]. It has been demonstrated that actigraphy sleep measures are sensitive enough to detect changes related to drug interventions [45]. In this trial, Actiwatch 2 (Philips Respironics, Inc., Murrysville, PA, USA) will be used to collect actigraphy data. Sleep will be measured in one night without study treatment, and then the actigraphy will monitor sleep continuously during the 6 nights in the treatment period (nights 1–6). Data will be analyzed with Actiwatch Spectrum and the latest version of Actiware software. The medium sensitivity setting will be used with an epoch length (i.e., the period of time that the actigraphy data is averaged) of 30 s [46].

**Discussion**
To improve palliative care, evidenced-based knowledge on the effects of therapeutic interventions is needed [47]. This randomized, double-blind, placebo-controlled, parallel-group, multicenter, clinical trial will provide important evidence concerning the short-time effectiveness of zopiclone for treatment of insomnia in palliative care. Results from this study of insomnia in patients with advanced cancer will inform clinical decision-making and provide guidance for treatment of sleep disturbance in these patients.

Recruiting patients with metastatic cancer is a major challenge, and research that involves patients with advanced cancer creates several ethical challenges. These patients are especially vulnerable and are at risk of several symptoms caused by the cancer disease and by short-time side effects of the therapy. It is important to recognize that the risks associated with research should not exceed the risks associated with usual care [48]. The patients included in this trial are exposed to some potential adverse effects from zopiclone. The risk is similar to that for sleep medications routinely administered to patients with sleep disturbance. It is possible that patients randomized to the control arm (placebo) may miss a beneficial therapy for 6 nights. However, today there is a clinical equipoise, and the best method to establish if zopiclone actually benefits or harms is a randomized placebo-controlled trial. Note also that placebos are frequently effective and can be as beneficial as supposedly active treatments [49]. Hence, the study is designed and will be performed for the best of the patients’ interest. Frequent consultations by phone with the patient during the treatment period will reveal if study drugs should be discontinued.

The primary endpoint in this clinical trial is patient-reported sleep quality in the last study night (night 6). Patient-reported outcome measures (PROMs) are especially important in palliative care, where symptom control is the major goal of interventions [50]. Research on insomnia management has primarily focused on specific sleep variables related to time intervals such as sleep initiation and sleep maintenance [51]. Recognizing the patients’ experience as more important in palliative care, we decided to use patient-reported sleep quality as more relevant to clinical practice.

In palliative care, many interventions are not supported by evidenced-based knowledge. This clinical trial assesses whether zopiclone, a frequently used sleep medication among palliative cancer care patients [24], is more effective than placebo in this cohort of patients.

**Organization**
The sponsor is St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway. Study personnel at the European Palliative Care Research Centre (PRC), NTNU are responsible for the data management for the study. The principal investigator has insurance coverage for this study through membership in the Drug Liability Association, Norway. The patients included in the study will be covered by this insurance.

**Trial status**
Participant recruitment is ongoing. Recruitment to the trial started in November 2016. In May 2017, it was decided to accept that both patients treated with an opioid and those not using an opioid can be included in the clinical trial. For this reason, the inclusion criterion “Regularly scheduled oral, subcutaneous, transdermal, or intravenous opioid treatment dose corresponding to step III at the WHO pain ladder with a stable dose for at least 2 days” was deleted from the protocol. The Regional Committee for Medical and Health Research Ethics, Norway approved this amendment in June 2017. The estimated date of completed recruitment is December 2019.
Additional file

Additional file 1: SPIRIT 2013 checklist: recommended items to address in a clinical trial protocol and related documents. (PDF 97 kb)

Abbreviations
AE: Adverse event; CBT-I: Cognitive behavioral therapy for insomnia; IMP: Investigational medicinal product; KPS: Karnofsky Performance Status; MCID: Minimal clinical important difference; NRS: Numerical rating scale; NWAK: Number of awakenings; PROM: Patient-reported outcome measure; RCT: Randomized controlled trial; SAE: Serious adverse event; SE: Sleep efficiency; SOL: Sleep onset latency; TST: Total sleep time; TWAK: Terminal wakefulness; WASO: Wake after sleep onset

Acknowledgements
Not applicable.

Funding
Financial support is provided by:

- A grant from the Central Norway Regional Health Authority awarded by the Liaison Committee for Central Norway (Project number 46083200)
- A grant from the Cancer Foundation, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway (Reference 15/9116-115/NISLIN)

The funders have no role in the trial design, the collection, analysis, and interpretation of data, or writing of the manuscript. No commercial interests are involved in the trial.

Availability of data and materials
The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions
GJ, ME, MUH, SK, PF, and PK designed the protocol and drafted the manuscript, and SXR, MT, ØP, and KS further aided in assessment and revision of the protocol and revised the manuscript. All authors have read and approved the final manuscript.

Ethics approval and consent to participate
This trial is conducted in accordance with ethical principles that have their origin in the Declaration of Helsinki and are consistent with The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH)/Good Clinical Practice and applicable regulatory requirements. We will obtain informed consent from all participants in the trial. Central ethical approval has been confirmed from the Regional Committee for Medical and Health Research Ethics (reference number 2016/353), which is valid for all Norwegian institutions.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1European Palliative Care Research Centre (PRC), Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology and St. Olavs hospital, Trondheim University Hospital, Trondheim, Norway. 2Cancer Clinic, St. Olavs hospital, Trondheim University Hospital, Trondheim, Norway. 3Department of Neurology and Clinical Neurophysiology, St. Olavs hospital, Trondheim, Norway. 4Palliative Care Unit, Telemark Hospital Trust, Skien, Norway. 5Department of Oncology, Vestfold Hospital Trust, Tønsberg, Norway. 6European Palliative Care Research Centre (PRC), Department of Oncology, Oslo University Hospital, and Institute of Clinical Medicine, University of Oslo, Oslo, Norway. 7Division of Applied Health Sciences, University of Aberdeen, Aberdeen, UK. 8Department of Anaesthesiology and Intensive Care Medicine, St. Olavs hospital, Trondheim University Hospital, Trondheim, Norway. 9Department of Circulation and Medical Imaging, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology NTNU, Trondheim, Norway.

Received: 19 October 2018 Accepted: 30 November 2018
Published online: 27 December 2018

References
1. Mystakidou K, Parpa E, Tsilika E, Patriaki M, Patriaki E, Galanos A, et al. Sleep quality in advanced cancer patients. J Psychosom Res. 2007;62(5):527–33.
2. Otte JL, Carpenter JS, Manchanda S, Rand KL, Skaar TC, Weaver M, et al. Systematic review of sleep disorders in cancer patients: can the prevalence of sleep disorders be ascertained? Cancer Med. 2015;4(2):183–200.
3. Mencadante S, Aielli F, Adile C, Ferrera P, Valle A, Cartoni C, et al. Sleep disturbances in patients with advanced cancer in different palliative care settings. J Pain Symptom Manag. 2015;50(6):786–92.
4. Jakobsen G, Engstrom M, Fayers P, Hermstad M, Kaasa S, Kloeke M, et al. Sleep quality with WHO Step III opioid use for cancer pain. BMJ Support Palliat Care. 2018. https://doi.org/10.1136/bmjspcare-2017-001399 [Epub ahead of print].
5. Sateia MJ, Lang BJ. Sleep and cancer: recent developments. Curr Oncol Rep. 2008;10(4):309–18.
6. Ohayon MM, Partinen M. Insomnia and global sleep dissatisfaction in Finland. J Sleep Res. 2002;11(3):349–66.
7. Pallesen S, Sivertsen B, Nordhus IH, Bjorvatn B. A 10-year trend of insomnia prevalence in the adult Norwegian population. Sleep Med. 2014;15(2):173–9.
8. Palesh OG, Roscoe JA, Mustian KM, Roth T, Savard J, Ancoli-Israel S, et al. Prevalence, demographics, and psychological associations of sleep disruption in patients with cancer: University of Rochester Cancer Center-Community Clinical Oncology Program. J Clin Oncol. 2010;28(2):292–8.
9. Savard J, Morin CM. Insomnia in the context of cancer: a review of a neglected problem. J Clin Oncol. 2001;19(3):895–908.
10. Mystakidou K, Parpa E, Tsilika E, Gennatas C, Galanos A, Vlahos L. How is sleep quality affected by the psychological and symptom distress of advanced cancer patients? Palliat Med. 2009;23(1):46–53.
11. Delgado-Guay M, Yennurajalingam S, Parsons H, Palmer JL, Bruera E. Association between self-reported sleep disturbance and other symptoms in patients with advanced cancer. J Pain Symptom Manag. 2011;41(5):819–27.
12. Palesh O, Aldridge-Gerry A, Zeitner JM, Koopman C, Neri E, Giese-Davis J, et al. Actigraphy-measured sleep disruption as a predictor of survival among women with advanced breast cancer. Sleep. 2014;37(2):383–42.
13. Kaneishi K, Kawabata M, Monta T. Single-dose subcutaneous benzodiazepines for insomnia in patients with advanced cancer. J Pain Symptom Manag. 2015;49(6):e1–2.
14. Induru RR, Walsh D. Cancer-related insomnia. Ann J Hosp Palliat Care. 2014;31(7):777–85.
15. Hugel H, ElshawejEH, Cole K, Skinner J, Irvine C. The prevalence, key causes and management of insomnia in palliative care patients. J Pain Symptom Manag. 2004;27(4):316–21.
16. Howell D, Oliver TK, Keller-Olaman S, Davidson JR, Garland S, Samuels C, et al. Sleep disturbance in adults with cancer: a systematic review of evidence for best practices in assessment and management for clinical practice. Ann Oncol. 2014;25(4):791–800.
17. Riemann D, Perlis ML. The treatments of chronic insomnia: a review of best practices in assessment and management for clinical practice. Sleep Med Rev. 2009;13(3):205–14.
18. Riemann D, Baglioni C, Bassetti C, Bjorvatn B, Dolsen Groselj L, Ellis JG, et al. European guideline for the diagnosis and treatment of insomnia. J Sleep Res. 2017;26(6):675–700.
19. Casault L, Savard J, Ivers H, Savard MH. A randomized-controlled trial of an early minimal cognitive-behavioural therapy for insomnia comorbid with cancer. Behav Res Ther. 2015;74:45–54.
20. Kvale EA, Shuster JL. Sleep disturbance in supportive care of cancer: a review. J Palliat Med. 2006;9(2):437–50.
21. Guzman-Marin R, Avidan AY. Sleep disorders in patients with cancer. J Community Support Oncol. 2015;13(4):1148–55.
22. Nutt DJ, Stahl SM. Searching for perfect sleep: the continuing evolution of GABAA receptor modulators as hypnotics. J Psychopharmacol. 2010;24(11):1601–12.
23. Hirst A, Sloan R. Benzodiazepines and related drugs for insomnia in palliative care. Cochrane Database Syst Rev. 2002(4):CD003346.
24. Kotlinska-Lemieszek A, Paulsen O, Kaasa S, Klepstad P. Polypharmacy in patients with advanced cancer and pain: a European cross-sectional study of 2282 patients. J Pain Symptom Manag. 2014;48(6):1145–59.
25. Farrar JT, Portenoy RK, Berlin JA, Kinman JL, Strom BL. Defining the clinically important difference in pain outcome measures. Pain. 2000;83(3):287–94.
26. Kaasa S, Apolone G, Klepstad P, Loge JH, Hjermstad MJ, Corli O, et al. Expert conference on cancer pain assessment and classification—the need for international consensus: working proposals on international standards. BMJ Support Palliat Care. 2011;1(3):281–7.
27. Yennurajalingam S, Atkinson B, Masterson J, Hui D, Urbauer D, Tu SM, et al. The impact of an outpatient palliative care consultation on symptom burden in advanced prostate cancer patients. J Palliat Med. 2012;15(1):20–4.
28. Kang JH, Kwon JH, Hui D, Yennurajalingam S, Bruera E. Changes in symptom intensity among cancer patients receiving outpatient palliative care. J Pain Symptom Manag. 2013;46(5):652–60.
29. Yennurajalingam S, Kwon JH, Urbauer D, Hui D, Reyes-Gibby CC, Bruera E. Consistency of symptom clusters among advanced cancer patients seen at an outpatient supportive care clinic in a tertiary cancer center. Palliat Support Care. 2013;11(6):473–80.
30. Yennurajalingam S, Chisholm G, Palla SL, Holmes H, Reuben JM, Bruera E. Self-reported sleep disturbance in patients with advanced cancer: frequency, intensity, and factors associated with response to outpatient supportive care consultation—a preliminary report. Palliat Support Care. 2013;11(2):33–43.
31. Yennurajalingam S, Kang JH, Cheng HY, Chisholm GB, Kwon JH, Palla SL, et al. Characteristics of advanced cancer patients with cancer-related fatigue enrolled in clinical trials and patients referred to outpatient palliative care clinics. J Pain Symptom Manag. 2013;45(3):S34–41.
32. Yennurajalingam S, Fristbee-Hume S, Palmer JL, Delgado-Guay MO, Bull J, Phan AT, et al. Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. J Clin Oncol. 2013;31(25):3076–82.
41. Buysse DJ, Alers DL, Vangamon E, Hall A, Albers J, Bolen J, et al. Edmonton Symptom Assessment System including constipation and sleep: validation in outpatients with cancer. J Pain Symptom Manag. 2015;49(5):945–52.
42. Ravnskjaer SK, Abildskov GM. Subjective and objective sleepiness in the active individual. Int J Neurosci. 1990;52(1–2):29–37.
43. Ware Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473–83.
44. Akerstedt T, Gillberg M. Subjective and objective sleepiness in the active individual. Int J Neurosci. 1990;52(1–2):29–37.
45. Lichstein KL, Stone KC, Donaldson J, Nau SD, Soeffing JP, Murray D, et al. Actigraphy validation with insomnia. Sleep. 2006;29(2):232–9.
46. Sadeh A. The role and validity of actigraphy in sleep medicine: an update. Sleep Med Rev. 2011;15(4):259–67.
47. Ancoli-Israel S, Martin JL, Blackwell T, Buenaver L, Liu L, Meltzer LI, et al. The SBEEM Guide to Actigraphy Monitoring: clinical and research applications. Behav Sleep Med. 2015;13(Suppl 1):S44–58.
48. Freedman B, Faks A, Weijer C. Demarcating research and treatment: a systematic approach for the analysis of the ethics of clinical research. Clin Res. 1992;40(4):653–60.
49. Finniss DG, Kapchuk TJ, Miller F, Benedetti F. Biological, clinical, and ethical advances of placebo effects. Lancet. 2010;375(9725):686–95.
50. Bausewein C, Simon ST, Benala H, Downing J, Mwangi-Powell FN, Davesson BA, et al. Implementing patient reported outcome measures (PROMs) in palliative care users’ cry for help. Health Qual Life Outcomes. 2011;9:27.
51. Kleinman L, Buysse DJ, Harding G, Lichstein K, Kalsekar A, Roth T. Patient-reported outcomes in insomnia: development of a conceptual framework and endpoint model. Behav Sleep Med. 2013;11(1):23–36.